Thor Medical ASA - Share capital increase in relation to Subsequent Offering is registered

01 Aug 2025 08:58 CEST

1.8.2025 08:58:53 CEST | Thor Medical ASA | Total number of voting rights and
capital

Oslo, Norway, 1 August 2025: Reference is made to stock exchange announcements
by Thor Medical ASA (the "Company") on 18 June 2025 regarding the completion of
the subsequent offering of a total of 4,000,000 new shares in the Company
raising a total of NOK 10 million in gross proceeds (the "Subsequent Offering").

The share capital increase relating the Subsequent Offering is now registered
with the Norwegian Register of Business Enterprises. The Company's share capital
is after the registration NOK 70,597,184 divided into 352,985,920 shares. Each
share has a nominal value of NOK 0.20 and represents one vote in the Company's
general meeting.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com



ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18606641/6332/Download%20announce
ment%20as%20PDF.pdf

More information:
Access the news on Oslo Bors NewsWeb site

651979_Download announcement as PDF.pdf